Literature DB >> 33517186

Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia.

Guillermo Montalban-Bravo1, Faezeh Darbaniyan2, Rashmi Kanagal-Shamanna3, Irene Ganan-Gomez4, Caleb A Class5, Koji Sasaki4, Kiran Naqvi4, Yue Wei4, Hui Yang4, Kelly A Soltysiak4, Kelly S Chien4, Carlos Bueso-Ramos3, Kim-Anh Do2, Hagop Kantarjian4, Guillermo Garcia-Manero4.   

Abstract

Chronic myelomonocytic leukemia (CMML) is characterized by myelomonocytic bias and monocytic proliferation. Whether cell-intrinsic innate immune or inflammatory upregulation mediate disease pathogenesis and phenotype or whether the degree of aberrant monocytic differentiation influences outcomes remains unclear. We compared the transcriptomic features of bone marrow CD34+ cells from 19 patients with CMML and compared to healthy individuals. A total of 1495 genes had significantly differential expression in CMML (q<0.05, fold change>2), including 1271 genes that were significantly upregulated and 224 that were significantly downregulated in CMML. Top upregulated genes were associated with interferon (IFN) alpha and beta signaling, chemokine receptors, IFN gamma, G protein-coupled receptor ligand signaling, and genes involved in immunomodulatory interactions between lymphoid and non-lymphoid cells. Additionally, 6 gene sets were differentially upregulated and 139 were significantly downregulated in patients with myeloproliferative compared to myelodysplastic CMML. A total of 23 genes involved in regulation of monopoiesis were upregulated in CMML compared to healthy controls. We developed a prediction model using Cox regression including 3 of these genes, which differentiated patients into two prognostic subsets with distinct survival outcomes. This data warrants further evaluation of the roles and therapeutic potential of type I IFN signaling and monopoiesis in CMML.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Chronic myelomonocytic leukemia; Interferon; Monopoiesis; Outcomes; RNA; Transcriptomic

Mesh:

Substances:

Year:  2021        PMID: 33517186     DOI: 10.1016/j.leukres.2021.106511

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Investigation of Interferon Gamma Activity Using Bioinformatics Methods.

Authors:  N E Hassan; A A Al-Janabi
Journal:  Arch Razi Inst       Date:  2021-11-30

2.  Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.

Authors:  Yue Wei; Rashmi Kanagal-Shamanna; Hong Zheng; Naran Bao; Pamela Pennington Lockyer; Caleb A Class; Faezeh Darbaniyan; Yue Lu; Kevin Lin; Hui Yang; Guillermo Montalban-Bravo; Irene Ganan-Gomez; Kelly A Soltysiak; Kim-Anh Do; Simona Colla; Guillermo Garcia-Manero
Journal:  Leukemia       Date:  2022-06-14       Impact factor: 12.883

3.  Analysis of the Clinical Significance and Safety of Interferon in the Treatment of Chronic Myeloproliferative Tumors.

Authors:  Fenglei Yin; Juan Yin; Weixing Xu; Shuchen Li; Wei Zhang; Juan Wang
Journal:  J Oncol       Date:  2022-05-16       Impact factor: 4.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.